Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Genetic Characteristics of HER2 Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) Regimen

NCT04276337 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04276337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04276337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Genetic Characteristics of HER2 Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) Regimen
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2018
Completion date
August 31, 2023
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, circulating tumor dna, her2-positive breast cancer